From the very beginning, Roche’s visionary founder focused his company on innovation and on establishing an international presence. This multinational presence reinforces our ability to offer our healthcare solutions and to anticipate needs in all regions of the world.
Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healthcare. Two-thirds of our Research and Development projects are being developed with companion diagnostics.
We are the world's number 1 in biotech with 17 biopharmaceuticals on the market. Over half of the compounds in our product pipeline are biopharmaceuticals, enabling us to deliver better-targeted therapies.
We have been at the forefront of cancer research and treatment for over 50 years, with medicines for breast, skin, colon, ovarian, lung and numerous other cancers.
We offer doctors profound information to guide treatments and to answer more patients’ questions than any other company. And our tests enable hospitals and labs to deliver that information quickly and reliably.
Closing share price
|FY, 2013||FY, 2014||FY, 2015|
|CHF46.8 b||CHF47.5 b||CHF48.1 b|
Revenue growth, %
Cost of goods sold
|CHF11.9 b||CHF13.4 b||CHF15.5 b|
|CHF34.8 b||CHF34.1 b||CHF32.7 b|
Gross profit Margin, %
Sales and marketing expense
|CHF8.4 b||CHF8.7 b||CHF8.8 b|
|CHF9.3 b||CHF9.9 b||CHF9.6 b|
General and administrative expense
|CHF2.6 b||CHF3.8 b||CHF2.7 b|
Operating expense total
|CHF20.3 b||CHF22.4 b||CHF21.1 b|
|(CHF1.6 b)||(CHF1.8 b)||(CHF1.6 b)|
|(CHF119 m)||CHF246 m||(CHF260 m)|
Income tax expense
|(CHF3.3 b)||(CHF3 b)||(CHF2.9 b)|
|CHF11.4 b||CHF9.5 b||CHF9.1 b|
Operating cash flow
|CHF15.8 b||CHF15.9 b||CHF15.3 b|